Published on 29 Apr 2024 on Zacks via Yahoo Finance
We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s ADMA portfolio of its three marketed commercial products and other pipeline updates when it reports first-quarter 2024 results.
Let’s see how things have shaped up for the quarter to be reported.
Factors at Play